This controlled study analysed thrombin generation, fibrinolysis and platelet activation in patients with allergic and non allergic asthma.164 asthmatics were compared to 72 healthy volunteer control group matched for age, sex, and BMI. Asthmatics had an altered thrombin generation profile, peak thrombin elevated by 41,5%, endogenous thrombin potential by 20.1%, (p<0.0001), faster thrombin formation: 15.5% shorter time to maximum, 11% shorter lag phase, respectively in asthmatics compared with controls. Asthmatics had impaired fibrinolysis: 14.4% longer clot lysis time, (p= 0.001), higher plasminogen, plasminogen activator inhibitor-1, (p<0.0001), endogenous thrombin potential, peak thrombin concentration, maximal prothrombin conversion rate (4.2%, 21.3%, 20.2%, 41.4%, 61%, respectively), 15.5% faster rate of thrombin formation, 10% lower thrombin decay capacity (all, p<0.0001) compared to controls. Asthmatics had 14.5% higher α2-macroglobulin, 5.6% lower antithrombin, unaltered prothrombin. α2-macroglobulin correlated positively with prothrombin (r=0.27, p<0.01) in allergic asthma. Non-allergic asthmatics (n=70, 42.6 %) had 17.5% longer CLT (p=0.02), which positively correlated with PAI-1 (r=0.19, p=0.049). Thrombin generation profile was not affected by allergy. α2-macroglobulin correlated positively with prothrombin (r=0.27, p<0.01) in allergic asthma. Serum PF4, but not P-s ; electine was 51% higher (p<0.0001) in asthmatics. The blood CD62P value did not differ in asthmatics and healthy controls. Allergic asthmatics (n=107) did not differ from non allergic asthmatics.
Mar 16, 2023
Jun 26, 2017
9
0
http://dl.cm-uj.krakow.pl:8080/publication/4169
Edition name | Date |
---|---|
ZB-126418 | Mar 16, 2023 |
Cybulska, Agnieszka
Kolasa-Trela, Renata
Brzezińska-Kolarz, Beata
Polok, Kamil
Kopytek, Magdalena
Morga, Rafał
Kuczia, Paweł
Maduzia, Dawid